Exchange-traded transparency

Lyxor has launched London's first exchange-traded note, which unlike its US counterparts is fully collateralised to minimise counterparty risk. But is there a downside to collateralisation? And just how transparent are exchange-traded products when it comes to counterparty risk? John Ferry reports

When Lyxor, the fund management subsidiary of French bank Société Générale and a leading provider of exchange-traded funds (ETFs), decided it wanted to list a product that would give European investors exposure to the price of gold, it faced two problems. First, the Ucits III regulations that govern the European fund market prohibit linkage to a single commodity. The answer? Wrap the product as an exchange-traded note (ETN) rather than an ETF.

Deciding to debut an ETN was the simple part. The

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

Credit risk & modelling – Special report 2021

This Risk special report provides an insight on the challenges facing banks in measuring and mitigating credit risk in the current environment, and the strategies they are deploying to adapt to a more stringent regulatory approach.

The wild world of credit models

The Covid-19 pandemic has induced a kind of schizophrenia in loan-loss models. When the pandemic hit, banks overprovisioned for credit losses on the assumption that the economy would head south. But when government stimulus packages put wads of cash in…

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here